Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rani Therapeutics Holdings, Inc. filings document the regulatory record of a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs. Form 8-K reports include quarterly and annual financial results, corporate updates, clinical and preclinical program disclosures, collaboration and license matters, and material agreements affecting the company’s operations and strategy.
The filing record also covers capital-structure activity involving Class A common stock, common warrants and pre-funded warrants, as well as Nasdaq continued-listing compliance notices. Proxy materials describe annual meeting matters, board elections, auditor ratification, governance procedures and stockholder voting mechanics for RANI’s public-company structure.
Imran Mir A, a director and 10% owner of Rani Therapeutics Holdings, Inc., purchased 36,000 shares of Class A Common Stock on July 21, 2026 at a weighted average price of about $0.69 per share, in multiple transactions between $0.688 and $0.69. After this purchase, he directly holds 2,119,334 Class A shares and has indirect interests in 74,139 Class A and 22,660,053 Class B shares through affiliated entities, for which he disclaims beneficial ownership beyond his pecuniary interest.
Rani Therapeutics Holdings, Inc. Chief Technical Officer Alireza Javadi reported two dispositions of Class A Common Stock related to restricted stock unit settlements. On March 27, 2026, he sold 386 shares at $0.78 per share to cover tax withholding obligations. On June 27, 2026, 309 shares at $0.74 per share were withheld and surrendered to the issuer to satisfy tax withholding obligations. Both transactions were reported late due to inadvertent administrative oversight.
Rani Therapeutics Holdings, Inc. director and Chief Executive Officer Imran Talat purchased 35,000 shares of Class A Common Stock on July 17, 2026 at $0.7198 per share in an open-market transaction, bringing his direct holdings to 469,736 shares. This total includes 12,343 shares held by VH Moll, L.P., for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The Rule 10b5-1 trading-plan checkbox is unchecked.
Rani Therapeutics Holdings, Inc. director and Chief Executive Officer Imran Talat reported a sale of 8,014 Class A shares at $1.41 on 2024-12-27 to cover tax withholding on restricted stock unit settlement. Between 2025-06-27 and 2026-06-27, an additional 52,001 shares were withheld or surrendered to satisfy RSU-related tax withholding obligations. The report states these transactions were filed late due to inadvertent administrative oversight and notes that reported holdings include 12,343 shares held by VH Moll, L.P., for which Talat disclaims beneficial ownership beyond his pecuniary interest.
Rani Therapeutics Holdings, Inc. reports that its Chief Financial Officer, Nicholas Maestas, received a compensation grant of a stock option on July 17, 2026 covering 2,000,000 shares of Class A common stock at an exercise price of $0.6973 per share. The option expires on July 16, 2036. According to the vesting terms, 25% of the shares vest on June 29, 2027, and 1/48th of the shares vest monthly over the following three years, subject to his Continuous Service under the company’s 2026 Inducement Plan. Following this award, Maestas holds options for 2,000,000 shares.
Rani Therapeutics Holdings, Inc. filed an initial ownership report on Form 3 for Chief Financial Officer Nicholas Maestas. The filing does not list any transactions or holdings in the non-derivative or derivative sections, serving purely as a baseline disclosure of his status as a reporting officer.
Rani Therapeutics Holdings, Inc. appointed Nicholas M. Maestas as Chief Financial Officer, principal financial officer, and principal accounting officer effective June 29, 2026, succeeding Svai Sanford. Maestas brings prior CFO and strategy experience from Tempest Therapeutics and finance roles at other biotechnology companies.
Under his June 24, 2026 offer letter, Maestas will receive a $500,000 annual base salary and be eligible for an annual bonus targeted at 75% of base salary. He will be granted a non-qualified option to purchase 2,000,000 shares of Class A common stock under Rani’s 2026 Equity Inducement Plan, vesting over four years, with 25% vesting after one year and the balance monthly over 36 months of continuous service.
The Board approved the new 2026 Equity Inducement Plan on June 28, 2026, reserving 5,500,000 shares of Class A common stock for inducement awards to new hires under Nasdaq Rule 5635(c)(4), which does not require stockholder approval. The plan’s terms are described as substantially similar to the company’s stockholder-approved 2021 Equity Incentive Plan.
Rani Therapeutics Holdings, Inc. reported that Chief Business Officer Kate McKinley received a grant of stock options covering 805,500 shares of Class A Common Stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the grant terms, one forty-eighth of the options vest monthly over four years starting April 1, 2026, as long as she maintains continuous service with the company. Following this award, she holds 805,500 stock options, aligning a portion of her compensation with the company’s future share performance.
Rani Therapeutics Holdings, Inc. reported that Chief Technical Officer Alireza Javadi received a grant of stock options covering 805,500 shares of Class A common stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the grant terms, 1/48th of the options vest monthly over four years starting April 1, 2026, as long as he maintains continuous service with the company. This is a compensation-related award, not an open-market purchase or sale.
Rani Therapeutics Holdings, Inc. reported that Chief Executive Officer Imran Talat received a grant of stock options covering 3,800,000 shares of Class A Common Stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the award’s terms, 1/48th of the underlying shares vest monthly over four years starting April 1, 2026, conditioned on his continued service with the company. Following this grant, Talat holds stock options on 3,800,000 shares directly, with no open-market buys or sells reported in this filing.